Apolipoprotein B and Cardiovascular Disease Risk: AACC Position Statement

This position statement comes not from cardiologists but from the laboratory scientists who actually run the blood tests — and that vantage point gives it unusual authority on a deceptively simple question: which number better predicts a heart attack, LDL cholesterol or apolipoprotein B?

The working group’s answer was apoB, and the reasoning is mechanical. Every atherogenic particle carries exactly one apoB molecule, so apoB counts the particles that lodge in the artery wall; LDL-C estimates only the cholesterol those particles happen to be carrying. When the two disagree — discordance, common in people with diabetes, metabolic syndrome, or high triglycerides — it is apoB that tracks the risk. The statement also made the practical case that apoB is well standardized and reliably measured, undercutting the long-standing objection that it was too unstandardized for routine use.

The document’s clinical significance is high precisely because of where it sits in the timeline. In 2009, mainstream guidelines were still firmly LDL-centric; this was a rigorous, citation-dense argument from the measurement experts that the field was tracking the wrong marker for a large group of patients.

The honest caveat is scope and adoption. A division working group’s position statement carries less institutional weight than a multi-society guideline, and it would take another decade and a half for the major guidelines to begin catching up.

We rate the evidence strong. It is a careful, technically grounded case for counting atherogenic particles directly — a principle that the most recent consensus statements have now largely endorsed.